221
Participants
Start Date
May 17, 2006
Primary Completion Date
September 1, 2007
Study Completion Date
September 14, 2007
Salmeterol/Fluticasone 50/250 mcg
Participant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers.
Salbutamol 100 mcg
This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol.
DISKUS™ powder inhalers
Participant received salmeterol and fluticasone using DISKUS™ powder inhalers.
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Buchholz
GSK Investigational Site, Geesthacht
GSK Investigational Site, Hamburg
GSK Investigational Site, Wedel
GSK Investigational Site, Hanover
GSK Investigational Site, Hanover
GSK Investigational Site, Kassel
GSK Investigational Site, Kassel
GSK Investigational Site, Bad Arolsen
GSK Investigational Site, Marburg
GSK Investigational Site, Eschwege
GSK Investigational Site, Braunschweig
GSK Investigational Site, Munich
GSK Investigational Site, Munich
GSK Investigational Site, Landsberg am Lech
GSK Investigational Site, Kaufbeuren
GSK Investigational Site, Erlangen
GSK Investigational Site, Uttenreuth
GSK Investigational Site, Rednitzhembach
GSK Investigational Site, Sonneberg
GSK Investigational Site, Würzburg
GSK Investigational Site, Cottbus
GSK Investigational Site, Chemnitz
GSK Investigational Site, Dresden
GSK Investigational Site, Greiz
Lead Sponsor
GlaxoSmithKline
INDUSTRY